SCHEDULE: Vivo Opportunity Exits Cidara Therapeutics Stake Post-Merger
Beneficial Ownership Amendment
Vivo Opportunity entities report zero beneficial ownership in Cidara Therapeutics, Inc. following the completion of a merger on January 7, 2026.
Summary
- Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity, LLC, Vivo Opportunity Cayman Fund, L.P., and Vivo Opportunity Cayman, LLC (collectively, "Vivo Opportunity") have filed an Amendment No. 3 to their Schedule 13G.
- The filing indicates that as of January 7, 2026, following the completion of a merger involving Cidara Therapeutics, Inc., Vivo Opportunity no longer beneficially owns any shares of Cidara Therapeutics, Inc.
- Their aggregate beneficial ownership is now 0 shares, representing 0% of the class of Common Stock.
- This amendment updates their previous beneficial ownership reporting for Cidara Therapeutics, Inc.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing. It reports a factual change in beneficial ownership due to a corporate event (merger) and does not provide new positive or negative information about Cidara Therapeutics' ongoing operations or financial health.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that a reduction to zero beneficial ownership by a significant institutional investor like Vivo Opportunity typically occurs after a corporate action such as a merger, acquisition, or a complete divestiture. This specific filing confirms the exit of Vivo Opportunity's stake in Cidara Therapeutics following a merger, which is a common outcome when a company is acquired or undergoes a significant restructuring that changes its equity structure.
Stakeholder Impact
- Shareholders of Cidara Therapeutics, Inc. should be aware that a significant institutional investor, Vivo Opportunity, has fully exited its position following a merger, which could impact institutional ownership statistics and trading liquidity.
Key Dates
| Date | Description |
|---|---|
| 01/07/2026 | Date of event requiring filing, specifically the completion of the Issuer's merger. |
| 02/13/2026 | Date of signing and filing of this Schedule 13G Amendment No. 3. |
Keywords
Cidara Therapeutics, Vivo Opportunity, Schedule 13G, beneficial ownership, merger, common stock, institutional ownership, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.